

Registration No. 333-87957  
Registration No. 333-68314  
Registration No. 333-104170  
Registration No. 333-125906  
Registration No. 333-145262  
Registration No. 333-220370  
Registration No. 333-220435  
Registration No. 333-225534

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-87957  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-68314  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-104170  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-125906  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-145262  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-220370  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-220435  
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-225534

*UNDER THE SECURITIES ACT OF 1933*

---

**PDL BioPharma, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or Other Jurisdiction of  
Incorporation or Organization)

94-3023969  
(I.R.S. Employer  
Identification Number)

59 Damonte Ranch Parkway, Suite B-375  
Reno, Nevada 89521

(Address of Principal Executive Offices) (Zip code)

(775) 832-8500

(Registrant's Telephone Number, Including Area Code)

---

1999 Stock Option Plan  
1999 Nonstatutory Stock Option Plan  
1993 Employee Stock Purchase Plan  
2002 Outside Directors Stock Option Plan  
2005 Equity Incentive Plan  
Amended and Restated 2005 Equity Incentive Plan  
Nonstatutory Inducement Stock Option Grant Notice and Nonstatutory Inducement Stock Option Agreement  
Inducement Restricted Stock Grant Notice and Inducement Restricted Stock Agreement  
(Full title of the Plans)

Christopher L. Stone  
Vice President, General Counsel and Secretary  
59 Damonte Ranch Parkway, Suite B-375  
Reno, Nevada 89521  
(Name and address of agent for service)

(775) 832-8500

(Telephone Number, Including Area Code, of Agent for Service)

**Copy to:**

**Karen E. Bertero  
Gibson, Dunn & Crutcher LLP  
333 South Grand Avenue  
Los Angeles, California 90071  
(213) 229-7000**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company	<input type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

## EXPLANATORY NOTE

### DEREGISTRATION OF SECURITIES

PDL BioPharma, Inc. (the “Registrant”) is filing these Post-Effective Amendments (“Amendments”) to those certain Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by the Registrant, as follows (note that the share numbers listed below do not take into account any corporate actions, such as stock splits, taken in the interim):

1. Registration Statement on Form S-8 (File No. 333-87957) for the registration of 1,925,000 shares of common stock of the Registrant, par value \$0.01 (“Shares”), issuable under the 1999 Stock Option Plan and the 1999 Nonstatutory Stock Option Plan.
2. Registration Statement on Form S-8 (File No. 333-68314) for the registration of 4,000,000 Shares issuable under the 1999 Stock Option Plan and the 1999 Nonstatutory Stock Option Plan.
3. Registration Statement on Form S-8 (File No. 333-104170) for the registration of 3,480,000 Shares issuable under the 1999 Nonstatutory Stock Option Plan and the 2002 Outside Directors Stock Option Plan.
4. Registration Statement on Form S-8 (File No. 333-125906) for the registration of 2,300,000 Shares issuable under the 2005 Equity Incentive Plan.
5. Registration Statement on Form S-8 (File No. 333-145262) for the registration of 3,400,000 Shares issuable under the 2005 Equity Incentive Plan and the 1993 Employee Stock Purchase Plan.
6. Registration Statement on Form S-8 (File No. 333-220370) for the registration of 1,000,000 Shares issuable under the Amended and Restated 2005 Equity Incentive Plan.
7. Registration Statement on Form S-8 (File No. 333-220435) for the registration of 1,201,200 Shares issuable under the Nonstatutory Inducement Stock Option Grant Notice and Nonstatutory Inducement Stock Option Agreement and the Inducement Restricted Stock Grant Notice and Inducement Restricted Stock Agreement.
8. Registration Statement on Form S-8 (File No. 333-225534) for the registration of 20,000,000 Shares issuable under the Amended and Restated 2005 Equity Incentive Plan.

The offerings contemplated by the Registration Statements have been terminated in connection with the Registrant’s previously disclosed voluntary plan of dissolution. In accordance with the undertaking contained in the Registration Statements (pursuant to Item 512(a)(3) of Regulation S-K), the Registrant hereby removes from registration any securities that were registered but unsold under the Registration Statements. Accordingly, these Amendments are being filed to deregister any securities covered by the above referenced plans which remain unissued as of the date of this filing.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Reno, State of Nevada, on this 2nd day of February, 2021.

PDL BIOPHARMA, INC.

By: /s/ Dominique Monnet

Dominique Monnet  
President and Chief Executive Officer

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dominique Monnet, Christopher L. Stone and Nathan Kryszak, and each of them, as his true and lawful attorney-in-fact and agent, with full and several power of substitution and resubstitution and to act without the others, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each such attorney-in-fact and agent full power and authority to do so and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each such attorney-in-fact and agent, or their substitute or resubstitute, each acting alone, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, the following persons have signed this Post-Effective Amendment No. 1 to the Registration Statements in the capacities and on the date(s) indicated.

Signature	Title	Date
/s/ Dominique Monnet	President, Chief Executive Officer and Director (Principal Executive Officer)	February 2, 2021
Dominique Monnet		
/s/ Edward A. Imbrogno, CPA	Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	February 2, 2021
Edward A. Imbrogno, CPA		
/s/ Elizabeth O'Farrell	Director	February 2, 2021
Elizabeth O'Farrell		
/s/ Alan Bazaar	Director	February 2, 2021
Alan Bazaar		
/s/ Natasha A. Hernday	Director	February 2, 2021
Natasha A. Hernday		
/s/ John P. McLaughlin	Director	February 2, 2021
John P. McLaughlin		